NASDAQ
Cadrenal Therapeutics, Inc. Common Stock (CVKD) has a free cash flow growth of -16.82% as of Friday, May 29, 2026. This represents a 39.27% increase compared to its 12-month average of -27.70%. Free cash flow growth tracks the year-over-year percentage change in cash generated after capital expenditures.
No price data available for this timeframe.